CN114585367A - 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物 - Google Patents

用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物 Download PDF

Info

Publication number
CN114585367A
CN114585367A CN202080071356.8A CN202080071356A CN114585367A CN 114585367 A CN114585367 A CN 114585367A CN 202080071356 A CN202080071356 A CN 202080071356A CN 114585367 A CN114585367 A CN 114585367A
Authority
CN
China
Prior art keywords
compound
calcification
weeks
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071356.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·佩雷罗·贝斯塔德
C·萨尔塞多·罗卡
M·D·费勒·瑞尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifu International Co ltd
Original Assignee
Sanifeld Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifeld Treatment Co ltd filed Critical Sanifeld Treatment Co ltd
Priority to CN202610080635.XA priority Critical patent/CN122080055A/zh
Publication of CN114585367A publication Critical patent/CN114585367A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080071356.8A 2019-11-11 2020-11-10 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物 Pending CN114585367A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610080635.XA CN122080055A (zh) 2019-11-11 2020-11-10 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382990.0 2019-11-11
EP19382990.0A EP3818983A1 (en) 2019-11-11 2019-11-11 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PCT/EP2020/081674 WO2021094331A1 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610080635.XA Division CN122080055A (zh) 2019-11-11 2020-11-10 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物

Publications (1)

Publication Number Publication Date
CN114585367A true CN114585367A (zh) 2022-06-03

Family

ID=68610132

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080071356.8A Pending CN114585367A (zh) 2019-11-11 2020-11-10 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物
CN202610080635.XA Pending CN122080055A (zh) 2019-11-11 2020-11-10 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610080635.XA Pending CN122080055A (zh) 2019-11-11 2020-11-10 用于治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物

Country Status (10)

Country Link
US (2) US20220339171A1 (cg-RX-API-DMAC10.html)
EP (2) EP3818983A1 (cg-RX-API-DMAC10.html)
JP (1) JP7808029B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220099957A (cg-RX-API-DMAC10.html)
CN (2) CN114585367A (cg-RX-API-DMAC10.html)
AU (1) AU2020381775B2 (cg-RX-API-DMAC10.html)
CA (1) CA3156023A1 (cg-RX-API-DMAC10.html)
IL (1) IL292118B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022004971A (cg-RX-API-DMAC10.html)
WO (1) WO2021094331A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003653A (es) 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
CN113712976B (zh) * 2021-10-21 2023-02-24 中国人民解放军海军军医大学 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs
US20250217970A1 (en) * 2023-12-28 2025-07-03 Case Western Reserve University Risk prediction of heart failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271915A1 (en) * 2013-03-15 2014-09-18 Laboratoris Sanifit, S.L. Use of derivatives containing c-o-p bonds in patients with kidney failure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
MX347723B (es) 2011-09-29 2017-05-10 Eth Zuerich Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
SMT202100406T1 (it) 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica
ES2762984T3 (es) 2015-12-11 2020-05-26 Eth Zuerich 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271915A1 (en) * 2013-03-15 2014-09-18 Laboratoris Sanifit, S.L. Use of derivatives containing c-o-p bonds in patients with kidney failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SANIFIT THERAPEUTICS S. A.: "Effect of SNF472 on Progression of Cardiovascular Calicification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)", pages 1 - 12, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/history/NCT02966028?A=54&B=54&C=merged#StudyPageTop> *
SANIFIT: "Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis", pages 1 - 3, Retrieved from the Internet <URL:https://www.sanifit.com/sanifit-announces-that-the-phase-2b-calipso-trial-of-snf472-met-its-primary-endpoint-in-slowing-the-progression-of-cardiovascular-calcification-in-patients-on-hemodialysis/> *

Also Published As

Publication number Publication date
IL292118B2 (en) 2026-08-01
CA3156023A1 (en) 2021-05-20
EP3818983A1 (en) 2021-05-12
AU2020381775B2 (en) 2026-03-26
KR20220099957A (ko) 2022-07-14
US20250295676A1 (en) 2025-09-25
JP2023500020A (ja) 2023-01-04
US20220339171A1 (en) 2022-10-27
AU2020381775A1 (en) 2022-04-14
JP7808029B2 (ja) 2026-01-28
CN122080055A (zh) 2026-05-26
IL292118B1 (en) 2026-04-01
MX2022004971A (es) 2022-06-08
IL292118A (en) 2022-06-01
WO2021094331A1 (en) 2021-05-20
EP4058030A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
US20250295676A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
JP6863618B2 (ja) 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
US20230248749A1 (en) Inositol phosphate compounds for use in increasing tissular perfusion
US12070469B2 (en) IP and IP analogs dosage regimens for the treatment of ectopic calcifications
RU2832087C1 (ru) Соединения инозитолфосфата для применения в лечении, замедлении прогрессирования или предупреждении сердечно-сосудистой кальцификации
HK40066584A (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
JP5485704B2 (ja) 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
JP2023141229A (ja) 高リン血症治療用医薬用組成物
HK40042797A (en) Inositol phosphates for the treatment of ectopic calcification
BR112021006004B1 (pt) Uso de inositol hexafosfato
HK40061817A (en) Use of derivatives with c-o-p bonds in patients with renal failure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066584

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250820

Address after: St Gallen

Applicant after: Weifu (International) Co.,Ltd.

Country or region after: Switzerland

Address before: Palma, Mallorca, Balearic Islands, Spain

Applicant before: Sanifeld treatment Co.,Ltd.

Country or region before: Spain